Citius Oncology Inc
Research Citius Oncology Inc (CTOR) on Bullrun: market cap USD 88.84M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCTOR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 88.84M
- Financial periodQ2 2026
- RevenueUSD 1.49M
- Net income-USD 8.92M
- Free cash flow-USD 4.71M
- Gross margin67.1%
Valuation Snapshot
latest market cap is USD 88.84M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 24.76M | -USD 11.24M | n/a | -0.34 | USD 3.92M | USD 3.80M | USD 44.87M |
| FY2024 | USD 0 | -USD 21.15M | -USD 4.87M | n/a | -0.31 | USD 112 | USD 3.80M | USD 46.14M |
| FY2023 | USD 0 | -USD 12.70M | USD 0 | n/a | -0.19 | USD 32.75K | n/a | USD 25.54M |
| FY2022 | USD 0 | USD 380.81K | USD 0 | n/a | 0.12 | USD 289.18K | n/a | USD 345.51K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 88.84M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 84.80M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 82.29M | 57.5 | n/a | n/a |
| 2023 | 2023-12-29 | USD 779.36M | 54.7 | n/a | n/a |
About Citius Oncology Inc
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Citius Oncology Inc's market cap?
Citius Oncology Inc's market capitalization is USD 88.84M.
What does Citius Oncology Inc do?
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.